Molecular Partners And Orano Med Dose First Patients In DLL3-Targeting Radio-DARPin Small Cell Lung Cancer Study

Molecular Partners AG Sponsored ADR

MOLN

0.00

Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712
Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles
Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.